Company Announcements

Quanterix named Paul Chapman president and CEO in July. Previously, he was vice president of the BioPharma Process Solutions at EMD Millipore.

Pacific Biosciences named David Botstein, PhD, to its Board in July. He is director of the Lewis-Sigler Institute for Integrative Genomics and Anthony B. Evnin Professor of Genomics at Princeton University.

Pacific Biosciences and Imec announced a multiyear collaboration in July to develop microchips for highly multiplexed single-molecule genetic analysis.

In August, Mike Glynn, CCO at Pacific Biosciences, resigned.

In July, TechVen Partners acquired SensiQ Technologies from FLIR Systems, which retains a minority interest. TechVen is a private equity firm led by Colin Cumming, former chief executive of ICx Technologies.

Life Technologies named IMGM Laboratories its first Certified Service Provider for Ion Torrent Personal Genome Machines in Germany.

Helicos BioSciences licensed certain patents in July to nucleotide composition and light systems for analyzing nucleic acid samples to Intelligent Biosystems for $1.6 million.

Seahorse Biosciences licensed a patent in August entitled “Methods Compositions and Kits for Assaying Mitochondrial Function” from Pioneer Valley Life Sciences Institute.

Hoefer, a Harvard Bioscience company, announced in August that VWR International will sell its premium line of electrophoresis products in Europe.

Blue Lion Biotech agreed in August to exclusively distribute MicruX Technologies’ iHVstat microfluidic electrophoresis system in North America.

In September, Aushon BioSystems named Martin Verhoef CEO. Previously, he was CEO at MiraDx and PrimeraDx. Founder and former CEO Peter Honkanen was named COO.

Product Introductions

Seahorse Bioscience launched in June the ready-to-use XF Palmitate-BSA FAO reagent, which eliminates the need for radioactivity in fatty acid oxidation assays.

Sales/Orders of Note

In August, Luminex was awarded a contract worth up to $11.6 million over three and a half years by the US Department of Defense Threat Reduction Agency. The contract funds the development of a prototype instrument that is a field deployable tool for rapid detection of biothreat agents and patient response biomarkers. The system will detect both protein and nucleic acid targets.